Press releases
-
-
-
-
Internal link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2
-
Internal link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
-
Internal link ProQR to Present at Cowen Health Care Conference
-
-
-
-
Internal link ProQR to Host R&D Day in New York on January 29
-
-
-
Internal link ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials
-
-
-
Internal link ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment
-
Internal link ProQR Announces Results for the Second Quarter of 2015
-
Internal link ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients
-
-
-
Internal link ProQR Therapeutics Announces Annual Shareholder Meeting
-
-
-